{
    "clinical_study": {
        "@rank": "134473", 
        "arm_group": [
            {
                "arm_group_label": "Cabozantinib (XL184) 140 mg", 
                "arm_group_type": "Experimental", 
                "description": "Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day."
            }, 
            {
                "arm_group_label": "Cabozantinib (XL184) lower dose", 
                "arm_group_type": "Experimental", 
                "description": "Cabozantinib (XL184) lower dose as tablets and placebo capsules administered orally once a day."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a\n      lower daily dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.\n      It will test if the lower dose results in similar progression free survival (PFS) and\n      overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse\n      events found in previous clinical trials of 140 mg."
        }, 
        "brief_title": "A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Medullary Thyroid Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject has a histologically confirmed diagnosis of MTC.\n\n          -  The subject has measurable disease that is metastatic as determined by the\n             investigator based upon computerized tomography (CT), magnetic resonance imaging\n             (MRI), bone scan, or X-ray taken within 28 days before randomization.\n\n          -  The subject has disease that is measurable per RECIST 1.1 as determined by the\n             investigator based upon CT or MRI images taken within 28 days before randomization.\n\n          -  The subject has documented worsening of disease (progressive disease) at screening as\n             compared with a previous CT scan or MRI image done within 14 months of screening.\n\n          -  The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of \u2264\n             1.\n\n          -  The subject has recovered from toxicities related to any prior treatments, unless\n             AE(s) are clinically non-significant and/or stable on supportive therapy.\n\n          -  The subject has adequate organ and marrow function.\n\n          -  Sexually active fertile subjects (male and female) must agree to use medically\n             accepted methods of contraception during the study and for 4 months after the last\n             dose of study treatment.\n\n          -  Female subjects of childbearing potential must not be pregnant at screening.\n\n        Exclusion Criteria:\n\n          -  The subject has previously received cabozantinib or has previously participated in a\n             cabozantinib clinical trial.\n\n          -  Receipt of any type of small molecule kinase inhibitor or hormonal therapy within  28\n             days or 5 half-lives, whichever is shorter, before randomization.\n\n          -  Receipt of any systemic anti-tumor therapy within 28 days of randomization (42 days\n             for nitrosoureas or/ mitomycin C).\n\n          -  Receipt of any other type of investigational agent within 28 days of randomization.\n\n          -  Receipt of radiation therapy within 28 days of randomization or radionuclide\n             treatment within 42 days of randomization.\n\n          -  The subject has untreated and/or active (progressing or requiring anticonvulsants or\n             corticosteroids for symptomatic control) central nervous system (CNS) metastasis.\n             Must have completed radiation therapy \u2265 28 days prior to randomization and be stable\n             without corticosteroids or anti-convulsant treatment for \u2265 10 days.\n\n          -  Treatment at therapeutic doses with oral anticoagulants or platelet inhibitors.\n\n          -  The subject has serious illness besides cancer.\n\n          -  Major surgery within 2 months before randomization. Complete healing from major\n             surgery must have occured 1 month before randomization and 7 days before\n             randomization for minor surgery.\n\n          -  The subject is unable to swallow multiple tablets or capsules.\n\n          -  The subject is pregnant or lactating.\n\n          -  The subject has had a diagnosis of another malignancy within 2 years before\n             randomization, except for superficial skin cancers, or localized, low-grade tumors\n             deemed cured and not treated with systemic therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896479", 
            "org_study_id": "XL184-401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cabozantinib (XL184) 140 mg", 
                "intervention_name": "Cabozantinib (XL184) 140 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cabozantinib (XL184) lower dose", 
                "intervention_name": "Cabozantinib (XL184) lower dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cabozantinib (XL184) 140 mg", 
                "intervention_name": "Placebo tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cabozantinib (XL184) lower dose", 
                "intervention_name": "Placebo capsule", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "thyroid cancer", 
            "medullary thyroid cancer"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at a Lower Dose/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients", 
        "other_outcome": {
            "description": "Adverse events are measured from informed consent and at least through 30 days after the date of a decision to discontinue study treatment.  Assessed for up to 31 months.", 
            "measure": "Safety and tolerability of cabozantinib as assessed by adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 31 months"
        }, 
        "overall_contact": {
            "last_name": "Exelixis Clinical Trials", 
            "phone": "1-888-EXELIXIS (888-393-5494)"
        }, 
        "overall_contact_backup": {
            "last_name": "Backup or International", 
            "phone": "650-837-7400"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS is measured from randomization until the date of first documented disease progression or date of death from any cause, whichever comes first. Assessed for up to 31 months.", 
            "measure": "Progression Free Survival", 
            "safety_issue": "No", 
            "time_frame": "Up to 31 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896479"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "ORR is the proportion of subjects with measurable disease at baseline and who have complete response (CR) or partial response (PR). Assessed for up to 31 months.", 
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 31 months"
        }, 
        "source": "Exelixis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Exelixis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}